Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors

Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire
ROCKVILLE, Md. -- March 3, 2014
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage
biopharmaceutical company, announced today the appointment of Mark P. Carthy
to the company's Board of Directors.
"We are very pleased to have Mark join Rexahn’s Board of Directors," said
Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. "Mark’s extensive
business and financing experience in the life sciences will be particularly
important as we continue the development of our three clinical stage oncology
candidates, Archexin^®, RX-3117, and Supinoxin™ (RX-5902) for the treatment of
multiple types of cancer.”
Dr. Chang Ahn, Ph.D., Chairman of the Board of Directors of Rexahn added,
“Mark’s significant industry experience and leadership, which spans over more
than 30 years in both pharmaceutical and smaller biotechnology companies, will
be a tremendous asset to the Company. We welcome Mark to the Board of
Directors and I am confident he will assist Rexahn in continuing to build
value for our stockholders while we develop potentially life-saving treatments
for patients."
Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare
venture capital management and advisory firm co-founded by Mr. Carthy in 2008.
Prior to founding Orion, Mr. Carthy was a Venture Partner and General Partner
at Oxford Bioscience Partners, an early stage venture capital firm that
provides equity financing and management assistance to companies within the
life sciences, technology, energy and healthcare sectors. From 1998 until
2000, Mr. Carthy served as the Biotechnology Portfolio Manager at Morningside
Ventures where he focused on early stage private equity investments.
Previously, he was Chief Business Officer of Cubist Pharmaceuticals and Senior
Director of Business Development at Vertex Pharmaceuticals. Mr. Carthy served
as a member of the board of the New England Venture Capital Association from
2006 until 2013 and was listed on the Forbes Midas List in 2009 as one of the
leading venture capitalists. He received a Bachelor of Chemical Engineering
from the University College Dublin, Ireland, a Master of Science in Chemical
Engineering from the University of Missouri and a Master of Business
Administration from the Harvard Graduate School of Business Administration.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated
to developing best-in-class therapeutics for the treatment of cancer. Rexahn
currently has three clinical stage oncology candidates, Archexin®, RX-3117,
and Supinoxin™ (RX-5902), and a robust pipeline of preclinical compounds to
treat multiple types of cancer. Rexahn has also developed proprietary drug
discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate
Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information,
please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal with information
that is not historical, these are forward-looking statements under the Private
Securities Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements about Rexahn’s plans, objectives, expectations and
intentions with respect to future operations and products and other statements
identified by words such as “will,” “potential,” “could,” “can,” “believe,”
“intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
other words of similar meaning or the use of future dates. Forward-looking
statements by their nature address matters that are, to different degrees,
uncertain. Uncertainties and risks may cause Rexahn’s actual results to be
materially different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties and risks
include, among others, the difficulty of developing pharmaceutical products,
obtaining regulatory and other approvals and achieving market acceptance; the
marketing success of Rexahn’s licensees or sublicensees; the success of
clinical testing; and Rexahn’s need for and ability to obtain additional
financing. More detailed information on these and additional factors that
could affect Rexahn’s actual results are described in Rexahn’s filings with
the Securities and Exchange Commission, including its most recent annual
report on Form 10-K and subsequent quarterly reports on Form 10-Q. All
forward-looking statements in this news release speak only as of the date of
this news release. Rexahn undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information, future
events or otherwise.
Contact:
The Trout Group LLC
Tricia Truehart, 646-378-2953
ttruehart@troutgroup.com